Royalty Pharma to Present at Upcoming Investor Conferences
NEW YORK, NY, November 27, 2024 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December.
Investors
Keep up to date with all our latest financial information and events, and access our archives for historical data, presentations, statements and reports.
Latest results
Portfolio metrics
35+
Approved products
17
Development-stage therapies
15
Blockbuster products (>$1bn in annual sales)
~13year
Portfolio duration
Financial metrics
$3.0bn
Portfolio Receipts
(2023)
(2023)
$2.8bn
Adjusted EBITDA
(2023)
(2023)
$2.0bn
Average annual capital deployed (2018-2023)
$4.0bn
Announced value of transactions (2023)
Stock information
RPRX
${{TradePrice}}
{{TradeDate}}
Latest quarterly earnings
Q3 2024
Corporate presentation
Latest releases
Royalty Pharma Announces Inaugural Prize For Impact In Healthcare
NEW YORK, NY, November 14, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or organizations who positively impact healthcare, was awarded to Micheal Milken. The prize includes a $250,000 charitable donation to support medical research or educational initiatives that further the recipient’s work.
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
NEW YORK, NY, November 7, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO for $125 million in cash upfront.
Royalty Pharma Reports Third Quarter 2024 Results
NEW YORK, NY, November 6, 2024 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and raised full year 2024 guidance for Portfolio Receipts.
